Post hoc analysis of the ANSWER trial (431 patients with cirrhosis and ascites): long-term albumin plus standard care improved 18-month survival when baseline serum albumin was ≤3.2 g/dL (HR 0.47), but not above 3.2 g/dL (HR 1.04).
Secondary analysisn = 431
Pompili et al. Pre-Treatment Serum Albumin Concentration Predicts Clinical Benefit of Long-Term Albumin in Patients With Cirrhosis and Ascites